Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

SML0937

Sigma-Aldrich

Darunavir

≥98% (HPLC)

Sinonimo/i:

TMC-114, UIC-94017, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl]

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C27H37N3O7S
Numero CAS:
206361-99-1
Peso molecolare:
547.66
Numero MDL:
MFCD09260006
Codice UNSPSC:
51111800
ID PubChem:
329825618
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

DMSO: 20 mg/mL, clear

Condizioni di spedizione

wet ice

Temperatura di conservazione

−20°C

Stringa SMILE

[H][C@]1([C@@H](OC(N[C@@H](CC2=CC=CC=C2)[C@@H](CN(S(C3=CC=C(N)C=C3)(=O)=O)CC(C)C)O)=O)CO4)[C@]4([H])OCC1

InChI

1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1
CJBJHOAVZSMMDJ-HEXNFIEUSA-N

Azioni biochim/fisiol

Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).
Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Michael S Saag et al.
JAMA, 320(4), 379-396 (2018-07-26)
Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for
Ninon Taylor et al.
Journal of acquired immune deficiency syndromes (1999), 75(1), e13-e20 (2016-11-01)
Hemeoxygenase-1 (HO-1) has recently been identified as a major driver of metaflammation and obesity-related insulin resistance (IR). Drug-induced IR increases cardiovascular risk within the HIV-1-infected population receiving antiretroviral therapy (ART). We therefore investigated a possible role of HO-1 in ART-induced
José Moltó et al.
The Journal of antimicrobial chemotherapy, 70(4), 1139-1145 (2014-12-20)
Maximizing ART efficiency is of growing interest. This study assessed the efficacy, safety, pharmacokinetics and economics of a darunavir dose-reduction strategy. This was a multicentre, randomized, open-label clinical trial in HIV-infected patients with plasma HIV-1 RNA <50 copies/mL while receiving
Natalia Stella-Ascariz et al.
The Journal of infectious diseases, 218(10), 1523-1530 (2018-07-10)
Tenofovir is a potent inhibitor of human telomerase. The clinical relevance of this inhibition is unknown. NEAT001/ANRS143 is a randomized trial that showed noninferiority over 96 weeks of ritonavir-boosted darunavir plus raltegravir versus tenofovir disoproxil fumarate/emtricitabine in 805 antiretroviral antiretrovrial-naive
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Ghosh A K, et al.
Bioorganic & Medicinal Chemistry, 15(24), 7576-7580 (2007)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.